1 week Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates Zacks

Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.11% and 6.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?